Cart
sales@molnova.com
BIBO 3304
CAS No. 191868-14-1
BIBO 3304( BIBO3304 )
Catalog No. M13008 CAS No. 191868-14-1
BIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 207 | In Stock |
|
| 5MG | 147 | In Stock |
|
| 10MG | 269 | In Stock |
|
| 25MG | 611 | In Stock |
|
| 50MG | 823 | In Stock |
|
| 100MG | 1107 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBIBO 3304
-
NoteResearch use only, not for human use.
-
Brief DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively.
-
DescriptionBIBO 3304 is a potent, selective, nonpeptide neuropeptide Y Y1 receptor antagonist with IC50 of 0.38 and 0.72 nM for human and the rat Y1 receptor, respectively; shows low affinity for the human Y2 receptor, human and rat Y4 receptor, human and rat Y5 receptor (IC50>1,000 nM); inhibits the feeding response induced by 1 mg NPY in mice, also completely abolishes PYY-induced inhibition of insulin release in vivo.Obesity Discontinued(In Vivo):BIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5 μM; p.o.) significantly increases serum insulin levels.
-
In Vitro——
-
In VivoBIBO3304 TFA (30 μg; bilateral paraventricular nucleus injection) attenuates the hyperphagia following fasting.BIBO3304 TFA (15-60 μg) dose-dependently inhibits the feeding reponse mediated by 1 μg NPY.BIBO3304 TFA (0.5?μM; p.o.) significantly increases serum insulin levels. Animal Model:Adult male Chbb:Thom rats weighing between 300 and 340 g Dosage:30 μg Administration:bilateral paraventricular nucleus injection Result:Attenuated the hyperphagia following fasting, especially during the first 2 h of refeeding.Animal Model:7-week-old C57BL/6JAusb mice Dosage:0.5?μM Administration:p.o.Result:Significantly increased serum insulin levels.
-
SynonymsBIBO3304
-
PathwayGPCR/G Protein
-
TargetNeuropeptide Y Receptor
-
RecptorNeuropeptide Y Receptor
-
Research AreaMetabolic Disease
-
IndicationObesity
Chemical Information
-
CAS Number191868-14-1
-
Formula Weight643.668
-
Molecular FormulaC31H36F3N7O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (155.36 mM)
-
SMILESC1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NC(CCCN=C(N)N)C(=O)NCC3=CC=C(C=C3)CNC(=O)N
-
Chemical Name(R)-2-(2,2-diphenylacetamido)-5-guanidino-N-(4-(ureidomethyl)benzyl)pentanamide 2,2,2-trifluoroacetate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Neuropeptide Y (22-3...
Neuropeptide Y (22-36), a 15 amino acid peptide, is a fragment of Neuropeptide Y.Neuropeptide Y (NPY) is a 36 amino-acid neuropeptide that is involved in various physiological and homeostatic processes in both the central and peripheral nervous systems. NPY has been identified as the most abundant peptide present in the mammalian central nervous system, which consists of the brain and spinal cord. It is secreted alongside other neurotransmitters such as GABA and glutamate.
-
Peptide YY (PYY), hu...
Peptide YY (PYY), a novel 36 amino-acid amidated hormone is a component of the complex neuroendocrine control process.Peptide YY (PYY) can mediate its effects through the Neuropeptide Y receptors.
-
MK-0557
MK-0557 is a selective and orally available antagonist of the neuropeptide Y5 receptor (Ki: 1.6 nM).
